Jubilant Life top gainer on FDA nod
By
Research Desk
about 10 years ago
Jubilant Life Sciences is currently the top gainer on the BSE, up over 5% at Rs.152 levels with an intra day high at Rs.155.
The stock is in the limelight on receiving final approvals from the US health regulator for sale of its generic anti-hypertensive drug, Valsartan tablets in the US markets. The company has also received its abbreviated new drug application (ANDA) for Mycophenolate Mofetil capsules and tablets, manufactured by the company's US arm Jubilant Cadista Pharmaceuticals Inc, and Rizatriptan tablets made at Jubilant Generics